1. Introduction {#s0005}
===============

Glioma is known as glioblastoma and also neuroepithelial tumors or neuroectodermal tumors for it occurs in neuroectodermal regions. More and more evidence shows that the body produces tumor-specific T cell-mediated immunity. However, tumor-specific immune response is not sufficient to eradicate the neoplasm. Antigen-induced T cell activation and proliferation is regulated by the positive and negative costimulatory receptor of the immunoglobulin superfamily ([@b0065]). Glioma is a highly lethal cancer, and it is also a typical tumor that can inhibit the effective anti-tumor immune response ([@b0100], [@b0005]). However, its pathogenesis remains unclear.

PD-L1, the homolog of B7.1/2 (CD80/86), shows the ability to co-stimulate molecules and regulate the immune system ([@b0050], [@b0025]). It is expressed in APCs and induced in the lymphoid and non-lymphoid peripheral tissues to make the outer periphery of PD-L1 for the regulation of activated T cells. IFN-γ is an effective cytokine for up-regulation of PD-L1, as IFN-γ response element in the promoter region of PD-L1. The expression of B7-DC (PD-L, another PD-1 ligand) is substantially confined to the medullary DCs and macrophages, not in peripheral tissues or wide expression in many cell types. Therefore the effect of inhibition of peripheral T cell-mediated immunity is less.

The immune system inspects and removes mutative cells, which are immune surveillance functions. Accordingly, the tumor cells may change phenotype to escape the attack of the immune response. Studies have shown that manipulation of the tumor microenvironment PD-L1/PD-1 molecule pathway and inducing expression of PD-L1 are associated with the immune suppression of the tumor, thereby allowing tumor progression and metastasis. PD-L1/PD-1 molecular pathway is the main mechanism of tumor immune escape, for the following reasons: First and most importantly, this approach is involved in the immune response, especially in the negative regulation of tumor origin and growth of the peripheral tissues; Secondly, the up-regulation of B7-H1 in the tumor microenvironment has also up-regulated the PD-1 in activated tumor infiltrating T cells, which may start a vicious suppressive loop; third, the pathway through a two-way signal interleaves contact innate and acquired immune regulation. These factors make the PD-1/B7-H1 molecular pathways that control the immune response in cancer and its progression play a central role. That is, the molecular axis of PD-L1/PD-1 that is controlled by the tumor led "good genes" to worse ([@b0075], [@b0020], [@b0010]).

In the present study, we show that the outer glioma cells in vivo have a high expression of PD-L1 and PD-L1 expressed by glioma cells reduces its immunogenicity in vitro. Thus, PD-L1 is a new mediator with an immunosuppressive effect in human gliomas.

2. Materials and methods {#s0010}
========================

(1)Cell culture. Human malignant glioma cell lines LN-229, U251MG and LN-308 were purchased from the Wuhan University typical species preservation centers, these cells are cultured according to the literature methods ([@b0105]).(2)Immunohistochemistry. Tumor specimens including 9 glioblastoma (WHO grade IV) and a mixed glioma (WHO III, female, *n* = 6, age range, 30--82 years old; males *n* = 4, age range 60--71 years old) were obtained from the operation of inpatient neurosurgery of our hospital. A normal brain tissue and normal brain tissue adjacent to tumor cells were used as control tissue. Immunohistochemistry was in accordance with the literature ([@b0105]). Frozen tissues were cut (20 μm) and fixed in acetone, using PD-L1 antibody (5H1) or isotype control antibody staining. The reaction product was observed with streptavidin-biotin staining (Shenzhen Nano Biotechnology Co., Ltd.). The percentages of positive staining of glioma cells as \<25%, 25--50%, 50--75%, and \>75% were quantitated.(3)PBMCs. Purified lymphocytes and DCs. PBMCs were isolated from the peripheral blood of normal healthy people ([@b0105]). Separated by MACS CD4^+^ and CD^+^ T cells (Miltenyi Biotec, Bergisch Gladbach, Germany). Co-culture experiments were in accordance with the literature ([@b0105]). Using ELISA (BD PharMingen) to detect cytokines that released into the supernatant (human IFN-γ, IL-2 and IL-10). The surface molecular markers of activated T cells were analyzed by flow cytometry. Mononuclear cells were obtained in RPMI1640 containing 10% fetal bovine serum with 1 h adhesion at 37 °C and cytokine GM-CSF (100 ng/ml, Leukomax; Sandoz, Basel, Switzerland) and IL-4 (40 ng/ml; PeproTech, Inc., Offenbach, Germany), after 6 days of culture these cells display an immature DC phenotype (CD14 and CD1a^+^ and HLA-DRlow, CD86low, CD80low/and CD83). Maturation was induced by LPS (5 μg/ml, S. typhi; Sigma L-7261) or TNF-α (PeproTech EC Ltd 200 units/ml). Mature DC HLA-DR expression and co-stimulatory molecules (CD86 and CD80).(4)Flow cytometry analysis. The immune cell surface markers were analyzed by CellQuest software (FACSCalibur cytometer; Becton Dickinson, Heidelberg, Germany). Count 10,000 events/antigen. The histogram was obtained by calculating SFI.(5)Co-culture experiments. Co-culture experiments were performed according to the literature ([@b0110]). 5 × 10^4^ glioma cells/well in 48-well culture plate types (Costar, Bodenheim, Germany), cultured with or without containing IFN-γ (500 units/ml) for 24 h to induce the expression of MHC-II PD -L1. The cells were washed with PBS, and 0.5 \* 10^6^ freshly purified T cell types (CD4^+^ and CD8^+^) were added to them. Then the cells were co-cultured in RPMI1640. To describe glioma -- correlation functions of immune cell interactions anti PD-L1 mAb (5H1) or a control antibody was added in accordance with the respective predetermined time or design. For all blocking experiments, co-culture was added in anti-PD-L1 (5H1). To detect the production of cytokines (human IFN-γ, IL-2 and IL-10), the supernatant was collected and analyzed by ELISA (BD PharMingen).(6)RNA extraction, cDNA synthesis and quantitative RT-PCR. Total RNA was extracted using Trizol (Invitrogen) according to the reagents operating instructions. RevertAid First Strand cDNA Synthesis Kit (MBI Fermentas, St. Leon-Rot, Germany) was used for cDNA synthesis and PCR amplification and DyNAmo Flash SYBR Green qPCR kit (Finnzymes Oy, Espoo, Finland) for Real-time PCR. Expression levels were calculated and normalized 18s rRNA. Primers 18srRNA and PD-L1 are shown in [Table 1](#t0005){ref-type="table"}.(7)Statistical analysis. Data processing using SPSS 11.0 software package, data were described in $\overline{x} \pm \text{sE}$ and *t*-test was used to compare the differences between two groups. *P* \< 0.05 indicates significant difference.

3. Results {#s0015}
==========

The expression of PD-L1 in human glioma cell lines. Expressed by the following by to detect. The PD-L mRNA expression of three kinds of human glioma cell lines was detected by qRT-PCR with or without the presence of IFN-γ (500 units/ml, 48 h). All glioma cell lines consisted of low-expressing PD-L1 mRNA. In the presence of IFN-γ, PD-L1 transcription (LN-308) increased 4.2-fold ([Fig. 1A](#f0005){ref-type="fig"}). Compared with IFN-γ, TNF-α has no effects on the expression of PD-L1mRNA (data not shown). Flow cytometric analysis of glioma cell lines revealed that the entire surface thereof has a composition formula of PD-L1 expression. After stimulation with IFN-γ, PD-L1 expression enhanced from 3.6 times to 17.2 times with SFI ratio (LN-229) ([Fig. 1B](#f0010){ref-type="fig"}).

1\. PD-L1 expression of Gliomas in vivo. By immunohistochemical staining, PD-L1 expressed in nine glioblastoma (WHOIV) and a mixed glioma. More than 50% of the tumor cells in glioblastoma tumors express PD-L1 (50--90%), and PD-L1 positive cells dispersed in the specimen uniformly, while in the adjacent normal tissue in the tumor or normal sample, no expression of PD-L1 has been found ([Fig. 2](#f0015){ref-type="fig"}).

2\. The functional correlation analysis of PD-L1 expression. Production of T cell cytokines and the inhibition of the expression of activation markers. To study the function and meaning of the PD-L1 expression derived from glioma cells, we cultured and purified the helper T cells with or without PD-L1 antibody using co-culture experiments. In addition to PD-L1, LN-229 glioma cells show a high expression of HLA-I composition formula and HLA-DR antigen. When the purified CD4^+^ T cells and LN-229 glioma cells were co-cultured, HLA-DR antigens and CD4^+^ T cell T cell receptors interacted, leading to the activation of T cells and the production of cytokines. Accordingly, HLA-I antigen of CD8^+^ T cells and glioma cells interact, leading to T cell activation. Cytokines (IFN-γ, IL-2 and IL-10) in the culture supernatants were detected by ELISA at predetermined release time points. Fresh not activated purified CD4^+^ and CD8^+^ T cells were co-cultured with glioma for 24 and 48 h. By adding anti-PD-L1 antibody, cytokines increased in co-culture supernatant (IFN-γ: CD4^+^ T cells 310 ± 12.9%, *P* = 0.017; CD8^+^ T cells: 159 ± 8.0%, *P* = 0.270; IL-2: CD4^+^ 176 ± 15.3%, *P* = 0.011; CD8^+^ 146 ± 5.7%, *P* = 0.338; [Table 2](#t0010){ref-type="table"}). PD-L1 took the most significant inhibition on the production of IFN-γ and IL-2 by CD4^+^ T cells. CD8^+^ T cells were also inhibited, but the production of cytokines did not reach statistically significant levels. The production of IL-10 varies between different donors. Generally, blockaded PD-L1 will increase the level of IL-10, but this effect is not significant (CD4^+^ T cells: 128 ± 5.3%, *P* = 0.096; CD8^+^ T cells: 119.2 ± 11.5%, *P* = 0.201) ([Table 2](#t0010){ref-type="table"}).

4. Discussion {#s0020}
=============

A variety of immune evasion strategies prompt cancer progression. Glioma is a typical suppressed tumor with anti-tumor immune response, and the factors include TGF-β, and IL-10 release, CD95L, CD70, or HLA-G ([@b0105]) expression. Glioma immunotherapeutic strategies eliminate immunosuppressive mechanisms or strengthen the anti-tumor immune response ([@b0080]). In the present study we demonstrate that PD-L1, one of the B7 family of co-stimulatory molecules, composed the formulation of glioma lines ([Fig. 1A](#f0005){ref-type="fig"}). Immunohistochemical analysis showed that PD-L1 was expressed in brain tumor specimens, but did not express near the site of the tumor and normal human brain tissue ([Fig. 2](#f0015){ref-type="fig"}). In vitro co-culture experiments, we demonstrated that PD-L1 significantly impaired anti-tumor immune response to T cell cytokine production (see [Table 2](#t0010){ref-type="table"}).

Under physiological and non-inflammatory conditions, PD-L1 is the main antigen presenting cell in the body, such as the expression ([@b0030]) of monocytes and DCs. However, under inflammatory conditions, PD-L1 is no longer limited to antigen presenting cells, it is also expressed by other cells such as endothelial and muscle cells ([@b0095]).

Our study provides evidence of PD-L1 expression in the brain in vivo. All malignant gliomas express PD-L1, but it was not expressed near the site of the tumor and normal human brain tissue ([Fig. 2](#f0015){ref-type="fig"}). This is similar to the culture of glioma cell lines in vitro ([Fig. 1A](#f0005){ref-type="fig"}). It remains unclear how and when to express PD-L1's by the glioma cells. In consistence with the previous results, RNA and protein levels of PD-L1 expression in glioma cells were significantly upregulated in inflammatory cytokines, such as IFN-γ stimulation, but there was no such effect in TNF-α ([Fig. 1A](#f0005){ref-type="fig"}).

PD-L1, expressed by glioma, is an anti-immune response inhibitor. This has been proved by co-culture experiments in vitro. With the presence of anti-PD-L1 antibody, the production of IFN-γ and IL-2 by CD4^+^ and CD8^+^ T cells were significantly strengthened, and IL-10 is only slightly raised. Recent studies have shown that activated T cells stimulated by PD-L1 lead to apoptosis ([@b0040]), and the proliferation of activated T cell and cytokine production will be inhibited by the combination of PD-1 and PD-L1 ([@b0045], [@b0030]). Recent studies also showed that the expression of PD-L1 in DCs exert an intense immunosuppressive effect on the activation of T cells. Thus, PD-L1 is an important molecule for induction and maintenance anergy of T cell under physiological conditions, which is conducive to the immune body from damage caused by excess immune response under normal physiological conditions, and to immunological tolerance to self-antigens ([@b0015], [@b0090]). In addition to the interaction between PD-1 and PD-L1, the inhibitory effect of PD-L1 can be mediated by other receptors ([@b0070], [@b0060], [@b0055]). Our results support that PD-L1 plays a negative regulatory function on T cell activation on the whole. Glioma associated PD-L1 expression is a mechanism of immune suppression of tumor escape immune recognition and destruction in the CNS.

5. Conclusion {#s0025}
=============

Glioma related inhibition of T cell in vivo by PD-L1 indicates that this co-stimulation molecule inhibits the T cell growth and cytokine production. Thus, PD-L1 glioma associated expression may affect the anti-immune response at the initial and secondary phase in vivo conditions. PD-L1 could inhibit T-cells at the start and DC functions to interfere with the primary anti-tumor immune response ([@b0015], [@b0090], [@b0035]). Moreover, PD-L1 can protect glioma cells from directly attacking the antigen-specific cytotoxic T cells ([@b0085]). The present results indicate that the effective blockage of the interaction between PD-1 and immune effector cells can be used as a potential therapeutic strategy for immunotherapy of glioma in vivo. It also means that the blocking of the PD-1/PD-L1 pathway has a potential value for immunotherapy of the glioma.
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![Using real-time quantitative RT-PCR to detect the PD-L1 mRNA expression of 48 h cultured human glioma cells with or without IFN-γ (500 units/ml).](gr1a){#f0005}

![Using flow cytometry to analyze the PD-L1 protein expression of 48 h cultured human glioma cells with or without IFN-γ (500 units/ml).](gr1b){#f0010}

![The expression of brain tumor samples of PD-L1 analyzed by immunohistochemistry. (A) and (B) glioma; Normal brain tissue (C).](gr2){#f0015}

###### 

Primers of 28srRNA and PD-L1.

  Gene        Sequence (5′--3′)
  ----------- ----------------------
  18s-for     CGGCTACCACATCCAAGGAA
  18s-rev     GCTGGAATTACCGCGGCT
  PD-L1-for   TCAATGCCCCATACAACAAA
  PD-L1-rev   TGCTTGTCCAGATGACTTCG

###### 

Functional consequences of PD-L1 expression for cytokine expression.

  Cytokine   Isotype Ab   HLA-I Ab                                  PD-L1 Ab                                   
  ---------- ------------ ----------------------------------------- ------------------------------------------ ---------------------------------------------
  IFN-γ      CD4^+^ T     100                                       54 ± 7[⁎⁎](#tblfn1){ref-type="table-fn"}   310 ± 12.9[⁎](#tblfn2){ref-type="table-fn"}
  CD8^+^ T   100          61 ± 5[⁎](#tblfn2){ref-type="table-fn"}   159 ± 8                                    
                                                                                                               
  IL-2       CD4^+^ T     100                                       37 ± 4[⁎⁎](#tblfn1){ref-type="table-fn"}   208 ± 15.3[⁎](#tblfn2){ref-type="table-fn"}
  CD8^+^ T   100          92 ± 6                                    146 ± 5.7                                  
                                                                                                               
  IL-10      CD4^+^ T     100                                       121 ± 10                                   128 ± 5.3
  CD8^+^ T   100          115 ± 8                                   120 ± 11.5                                 

LN-229 glioma cells with the same kind of immune cells and CD4^+^ and CD8^+^ T cells were co-cultured for 48 h with the same type of antibodies, HLA-I antibody and PD-L1 antibody (5H1), and regulation of PD-L1 on cytokine IFN-γ, IL-2 and IL-10 was evaluated. Cytokine levels stimulated by the same antibodies were taken as 100, compared with their relative levels of cytokines.

Indicates *P* \< 0.01.

Indicates *P* \< 0.05.
